The stock of Abbott Laboratories (NYSE:ABT) last traded at $104.94, down -1.16% from the previous session.
ABT stock price is now -6.42% away from the 50-day moving average and -1.55% away from the 200-day moving average. The market capitalization of the company currently stands at $182.56B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On May 30, 2023, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock keeping its target price maintained at $112, while ‘Wolfe Research’ rates the stock as ‘Underperform’
In other news, Earnhardt Lisa D, EXECUTIVE VICE PRESIDENT sold 22,852 shares of the company’s stock on May 07 ’24. The stock was sold for $2,428,119 at an average price of $106.25. Upon completion of the transaction, the EXECUTIVE VICE PRESIDENT now directly owns 61,462 shares in the company, valued at $6.45 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01 ’24, EXECUTIVE VICE PRESIDENT Salvadori Daniel Gesua Sive sold 963 shares of the business’s stock. A total of $114,116 was realized by selling the stock at an average price of $118.50. This leaves the insider owning 125,697 shares of the company worth $13.19 million. A total of 0.73% of the company’s stock is owned by insiders.
During the past 12 months, Abbott Laboratories has had a low of $89.67 and a high of $121.64. As of last week, the company has a debt-to-equity ratio of 0.38, a current ratio of 1.60, and a quick ratio of 1.11.
According to the Medical Devices Company, earnings per share came in at 1.08, beating analysts’ expectations of 1.05 by 0.03. This compares to $0.75 EPS in the same period last year. The net profit margin was 13.91% and return on equity was 14.80% for ABT. The company reported revenue of $9.96 billion for the quarter, compared to $9.75 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.23 percent. For the current quarter, analysts expect ABT to generate $10.37B in revenue.
